NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

NKGen Biotech (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in NK cell therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. Paul Y. Song, MD, Chairman and CEO of NKGen, will deliver a virtual presentation and engage in one-on-one meetings with investors.

Key points:

• The virtual presentation will be available on-demand starting September 9, 2024, at 7:00 AM Eastern Time
• Registered participants can submit questions after the presentation
• A webcast of the pre-recorded presentation will be accessible on NKGen's website
• The webcast replay will be available for 90 days following the presentation

This event provides an opportunity for NKGen to showcase its innovative NK cell therapeutics and engage with potential investors.

SANTA ANA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and CEO of NKGen, will participate in a virtual presentation and one-on-one meetings at the H.C. Wainwright 26^th Annual Global Investment Conference, on September 9-11, 2024.

The virtual presentation will be available on-demand for registered participants through the H.C. Wainwright conference portal starting at 7:00 AM Eastern Time on Monday, September 9, 2024. Registered participants can submit their questions to NKGen after the presentation has become available. Dr. Song will also be available for virtual one-on-one investor meetings during the conference.

For more information about the conference and to register for a one-on-one meeting, please visit the conference website at https://hcwevents.com/annualconference/

A webcast of the pre-recorded presentation can be accessed under the Events and Presentations page in the Investors section of the Company’s website at www.nkgenbiotech.com. An archived replay of the webcast will be available for 90 days following the presentation.

About NKGen Biotech

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.

Forward-Looking Statements

Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans and expected timing for developing SNK01 and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Internal Contact:
Denise Chua, MBA, CLS, MT (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com

External Contacts:
Chris Calabrese
Managing Director
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com

Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com

FAQ

When is NKGen Biotech (NKGN) presenting at the H.C. Wainwright Global Investment Conference?

NKGen Biotech (NKGN) will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. The virtual presentation will be available on-demand starting September 9, 2024, at 7:00 AM Eastern Time.

Who will represent NKGen Biotech (NKGN) at the H.C. Wainwright conference?

Paul Y. Song, MD, Chairman and CEO of NKGen Biotech (NKGN), will represent the company at the H.C. Wainwright 26th Annual Global Investment Conference.

How can investors access NKGen Biotech's (NKGN) presentation at the H.C. Wainwright conference?

Investors can access NKGen Biotech's (NKGN) presentation through the H.C. Wainwright conference portal for registered participants. A webcast will also be available on the Events and Presentations page in the Investors section of NKGen's website.

How long will the replay of NKGen Biotech's (NKGN) presentation be available?

The archived replay of NKGen Biotech's (NKGN) presentation webcast will be available for 90 days following the presentation on the company's website.